Niraparib and Polatuzumab Vedotin-piiq

In the database of official manuals used in the service creation an interaction registered by statistical results of studies was found, which can either lead to negative consequences for the patient health or strengthen a mutual positive effect. A doctor should be consulted to address the issue of joint drug administration.

Consumer information for this interaction is not currently available.MONITOR: Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with niraparib. Some cases were fatal, and the duration of therapy with niraparib in patients who developed MDS/AML varied from less than 1 month to 2 years. All patients had previous chemotherapy with platinum agents while some patients also received DNA-damaging agents and radiotherapy. MANAGEMENT: Caution is advised if niraparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed weekly for the first month, monthly for the next 11 months, and periodically thereafter. Do not start niraparib until patients have recovered from hematological toxicity caused by previous chemotherapy (Grade 1 or less). If hematological toxicities have not resolved within 4 weeks after interruption, discontinue niraparib and refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue niraparib. Patients should be advised to contact their physician if they experience weakness, fatigue, fever, weight loss, infections, shortness of breath, unusual bleeding or bruising, or blood in urine or stool. References "Product Information. Zejula (niraparib)." Tesaro Inc., Waltham, MA.

MONITOR: Coadministration with other myelosuppressive agents may potentiate and prolong the bone marrow toxicity associated with niraparib. Myelodysplastic syndrome (MDS) and acute myeloid leukemia (AML) have been reported in patients treated with niraparib. Some cases were fatal, and the duration of therapy with niraparib in patients who developed MDS/AML varied from less than 1 month to 2 years. All patients had previous chemotherapy with platinum agents while some patients also received DNA-damaging agents and radiotherapy.

MANAGEMENT: Caution is advised if niraparib is prescribed with other myelosuppressive agents. Complete blood counts should be performed weekly for the first month, monthly for the next 11 months, and periodically thereafter. Do not start niraparib until patients have recovered from hematological toxicity caused by previous chemotherapy (Grade 1 or less). If hematological toxicities have not resolved within 4 weeks after interruption, discontinue niraparib and refer the patient to a hematologist for further investigations, including bone marrow analysis and blood sample for cytogenetics. If MDS/AML is confirmed, discontinue niraparib. Patients should be advised to contact their physician if they experience weakness, fatigue, fever, weight loss, infections, shortness of breath, unusual bleeding or bruising, or blood in urine or stool.

Niraparib

Generic Name: niraparib

Brand name: Zejula

Synonyms: n.a.

What is Niraparib?

Polatuzumab Vedotin-piiq

Generic Name: polatuzumab vedotin

Brand name: Polivy

Synonyms: Polatuzumab vedotin, Polatuzumab Vedotin

What is Polatuzumab Vedotin-piiq?